Volume 23, Issue 2 - Regulatory Writing Basics

Adverse event reporting: A brief overview of MedDRA

Author: Gregory Morley

Abstract

Download the full article

References

1. Wood KL. The medical dictionary for drug regulatory affairs (MEDDRA) project. Pharmacoepidemiol Drug Saf 1994;3(1):7–13.
2. Mozzicato P. MedDRA: an overview of the Medical Dictionary for Regulatory Activities. Pharm Med 2009;23(2):65–75.
3. Brown E, Douglas S. Tabulation and analysis of pharmacovigilance data using the medical dictionary for regulatory activities. Pharmacoepidemiol Drug Saf 2000;9(6):479–89.
4. MedDRA. MedDRA® data retrieval and presentation: points to consider ICH – Endorsed Guide for MedDRA Users on Data Output. 2014.
5. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS ONE 2012;7(7):e41174.
6. Tonéatti C, Saïdi Y, Meiffrédy V, Tangre P, Harel M, Eliette V, et al. Experience using MedDRA for global events coding in HIV clinical trials. Contemp Clin Trials 2006;27(1):13–22.
7. Kondro W, Sibbald B. Drug company experts advised staff to withhold data about SSRI use in children. CMAJ 2004;170(5):783.
8. Ben Goldacre. Bad Pharma: how medicine is broken, and how we can fix it. London, UK: Fourth Estate; 2013.